Obesity contributes to fibrosis and organ dysfunction across the liver, heart, and kidneys. Nordic Bioscience’s biomarkers offer non-invasive insights into fibrotic activity, disease progression, and treatment response. These tools support precision medicine approaches in obesity by helping identify at-risk individuals, guide therapeutic strategies, and monitor the impact of lifestyle or pharmacological interventions.
Biomarkers in obesity and metabolic diseases
Obesity is a driving force for multi-organ fibrosis, which contributes to progressive damage in the liver, heart, and kidneys. Nordic ProteinFingerPrint™ biomarkers quantify fibrogenic activity, providing early risk assessment, prognostic insights, and objective monitoring of therapeutic response in people with obesity, type 2 diabetes and other metabolic diseases.
